| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Neuropathic pain remains a major clinical problem and thus development of effective and safe therapy for the pain is awaited. miR-17-92 cluster microRNAs are critical for chronic neuropathic pain. These microRNAs are predicted to target many genes, some of which are indeed responsible for neuropathic pain. Drugs modifying these gene function exerted potent analgesia. Therefore, miR-17-92 may provide an opportunity for development of neuropathic pain therapy.
|
